


Appendices



APPENDIX
TABLE OF CONTENTS

Appendices	Cover Page
Appendix A	Current Rx Package Insert for Pravachol Tablets
Appendix B	Post Marketing Surveillance: Table and Summary of Deaths
Appendix C	Post Marketing Surveillance: Overdose Reports; Council for International Organization of Medical Science
Appendix D	Post Marketing Surveillance: Summaries of Serious Adverse Event Reports; Hepatic Failure, Jaundice, and Hepatitis
Appendix E	10 mg Dose Response Studies: Summaries of Efficacy Results
Appendix F	PREDICT: Abbreviated Written Consent Form
Appendix G	PREDICT: Summary of Serious Adverse Events
Appendix H	PREDICT/OPTIONS: Starter Kit Elements
Appendix I	PREDICT/OPTIONS: PRAVACARE Educational Program Materials
Appendix J	OPTIONS: Summary of Serious Adverse Events
Appendix K	Schematic Flow Chart for Toll Free Information Line

Pravachol 10 mg Tablets OTC
Advisory Committee Briefing Book

**Joint Meeting of Nonprescription Drugs Advisory Committee and
Endocrinologic & Metabolic Drugs Advisory Committee**

July 14, 2000

**Advisory Committee Meeting
Briefing Book
Appendices**

For the Rx-to-OTC Switch of:

NDA 21-198, Pravachol[®] (Pravastatin Sodium) 10mg Tablets

Bristol-Myers Squibb Company
Worldwide Consumer Medicines
1350 Liberty Avenue
Hillside, New Jersey 07207-6050

AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION